Current status of oral tirzepatide
As of mid-2025, tirzepatide is available as injectable (brand name Mounjaro; compounded oral versions are not authorized, regulated, or recommended). Oral tirzepatide tablets have not been approved by the FDA or by most other major global regulators. Development and ongoing clinical trials are actively evaluating safety and efficacy of oral formulations, but these investigational products are not yet commercially available to patients.
What regulators require for oral tirzepatide approval
Phase and design milestones
Regulatory approval depends on completing predefined study phases and meeting primary and secondary endpoints. For oral tirzepatide, sponsors typically must show noninferior or superior HbA1c and body weight reductions compared with approved comparators, plus safety across gastrointestinal and other common adverse events. Manufacturing and stability studies for oral tablets must also satisfy regulators before submission and review.
| Milestone | Estimated timeline or status | Why it matters |
|---|---|---|
| Phase 3 evidence (HbA1c, body weight) | Data evolving; trials ongoing as of 2025 | Regulators require robust efficacy and safety |
| Regulatory submission (e.g., NDA) | Not yet filed for oral formulation in many regions | Submission starts formal review; timing varies |
| Regulatory review and potential approval | Unknown if/when approved; post-approval likely several years away | Review periods commonly 6–12 months if complete |
Manufacturer plans and trial landscape
Eli Lilly has publicly stated that oral tirzepatide remains in clinical development. Trial registries and sponsor communications indicate ongoing studies to determine optimal dosing, absorption strategies (e.g., formulation technologies to protect the peptide in the gut), and long-term safety. No confirmed launch date has been published, and timelines disclosed by companies are typically wide ranges subject to change based on results and regulatory feedback.
What patients should watch for
While waiting for authorized oral tirzepatide, patients should rely on currently approved treatments (injectable GLP-1 receptor agonists or other options) and discuss evidence-based alternatives with their clinician. Track credible updates from the FDA, EMA, or other national regulators; official approval letters; and post-approval labeling. Avoid compounded or non-authorized oral versions, as these lack regulatory oversight, standardized dosing, and proven stability.
Comparing oral vs injectable GLP-RA options today
- Approved injectables (e.g., Mounjaro) have established safety/efficacy data and are covered by many plans when indicated.
- Oral formulations are investigational; no authorized oral tirzepatide is currently on the market.
- Compounded oral versions are unregulated, may have variable absorption, and are not supported by manufacturer labeling.
Bottom line on availability
There is no reliable date for when authorized tirzepatide pills will become available. Development is active, but approval and commercial launch depend on successful trials, regulatory review, and manufacturing readiness. Patients and clinicians should use currently approved therapies and check official regulatory channels for any future updates. Claims of imminent availability are speculative until an approved product is formally marketed.